Aurobindo obtains FDA nod for generic Ovcon
Aurobindo's Rhuzdah is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.
The Food and Drug Administration has cleared Aurobindo’s Rhuzdah (norethindrone and ethinyl estradiol tablets), 0.4mg/0.035mg.
The medication, a generic of Warner Chilcott’s Ovcon-35 tablets, is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.
[Read more: Aurobindo obtains FDA approval for generic Colcrys]
Rhuzdah had a market value of approximately $536,000 for the 12 months ending August 2022, according to IQVIA.